CN1794973A - Preserved ophthalmic compositions - Google Patents
Preserved ophthalmic compositions Download PDFInfo
- Publication number
- CN1794973A CN1794973A CNA2004800139343A CN200480013934A CN1794973A CN 1794973 A CN1794973 A CN 1794973A CN A2004800139343 A CNA2004800139343 A CN A2004800139343A CN 200480013934 A CN200480013934 A CN 200480013934A CN 1794973 A CN1794973 A CN 1794973A
- Authority
- CN
- China
- Prior art keywords
- composition
- component
- amount
- compositions
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Ophthalmic compositions include a carrier component, an oxy-chloro component present at an amount effective in preserving the composition, and at least one additional component, e.g. a borate component and/or a glycerin component present in an amount effective to enhance a preservative efficacy of the composition. The compositions preferably also include one or more other components, such as therapeutic components, e.g., quinoxaline components, and polyanionic components effective to provide the compositions with one or more functionalities.
Description
Technical field
The present invention relates to preserved ophthalmic compositions and make the ophthalmic composition preserving method.More specifically, the ophthalmic composition that the present invention relates to comprises, be used for the ophthalmic composition to the ocular delivery medicine, the ophthalmic composition for the treatment of xerophthalmia (dry eye) and other nursing eye, contact lens (contactlens) care composition or the like, described ophthalmic composition has benefited from anticorrosion.
Background technology
According to the type of compositions, ophthalmic composition is used at least a antiseptic usually.Some therapeutic agent that is included in the described compositions often also can be because of its inactivation to some antiseptic sensitivity.If the concentration of antiseptic is lower, then can in some cases this side effect be reduced to minimum or with its elimination.In addition, the low side effect that also helps preventing that eye from stimulating or other can be caused by some antiseptic of the concentration of antiseptic.Yet the concentration of antiseptic is low in some cases can make compositions can't pass through some standard, for example test of USP, EP-A and/or EP-B inhibitor effectiveness (efficacy) or standard.And antiseptic also can be in time and inactivation, thereby require the initial concentration of antiseptic higher.Some situation can make described inactivation be easier to take place, and for example is exposed to one or more compositions that are included in the compositions.
Multiple ophthalmic composition, for example use of solution, emulsion and suspension etc., with to eye or by the ocular administration therapeutic agent or the treatment component combine.For example, a kind of O/w emulsion can be used as a kind of carrier that is applied to the treatment component of eye.Described compositions is benefited from effectively anticorrosion usually, for example uses not to compositions or uses the mankind of compositions or antiseptic and/or the concentration of preservatives that animal produces remarkable illeffects.
Need a kind of ophthalmic composition, the effect of preservative component improves in the described compositions, thereby can use antiseptic and/or the lower antiseptic of concentration that does not produce described illeffects.
Summary of the invention
Found new preserved ophthalmic compositions and made the ophthalmic composition preserving method.The invention provides effective antiseptical ophthalmic composition, the ophthalmic composition that preferred inhibitor effectiveness improves.The present invention guarantees that advantageously compositions can use the reduction illeffects, for example the lower preservative component of the preservative component of side effect and/or concentration.
With regard to broad aspect, the invention provides ophthalmic composition, described ophthalmic composition comprises carrier component, preferably includes aqueous components, the treatment component of treatment effective dose is so that chlorine oxygen component that the effective antiseptical amount of compositions exists and the borate component that exists with the amount of effective raising compositions inhibitor effectiveness.In one embodiment, for the essentially identical compositions of no borate component, the inhibitor effectiveness of said composition or chlorine oxygen component increases.Preferably, compositions comprises the glycerin component that exists with the amount that further effectively improves the compositions inhibitor effectiveness.The present invention also provides and improves chlorine oxygen component effect in the ophthalmic composition, preferably improves the method for its inhibitor effectiveness.Described method can comprise that a certain amount of borate component that will effectively improve the effect of chlorine oxygen component combines with the ophthalmic composition that comprises chlorine oxygen component.
In one embodiment, ophthalmic composition comprises aqueous components and oily components, and advantageously is the O/w emulsion form.
In one embodiment, the treatment component is quinoxaline (quinoxa1ine) component.The quinoxaline component includes but not limited to, for example quinoxaline (as 2-imidazoline-2-base aminoquinoxaline), its salt (as its can eye usefulness acid-addition salts) and composition thereof.
In one embodiment, the quinoxaline component has structural formula:
With its can eye usefulness acid-addition salts and composition thereof.R
1Can be H, comprise the alkyl of 1 to 4 carbon atom or comprise the alkoxyl of 1 to 4 carbon atom, R
2Can be H, comprise the alkyl of 1 to 4 carbon atom, as methyl or comprise the alkoxyl of 1 to 4 carbon atom.2-imidazoline-2-base amino can be arranged in 5-, the 6-of quinoxaline ring, the optional position of 7-, 8-.R
3, R
4And R
5Can be arranged in any one position of the remaining 5-of quinoxaline ring, 6-, 7-, 8-.Each 5-, 6-, 7-, 8-can be Cl, Br, H or comprise the alkyl of 1 to 3 carbon atom, as methyl.Quinoxaline can have, and for example, but is not limited to one of following structural formula:
A kind of quinoxaline component that is highly profitable comprises and is selected from 5-bromo-6-(2-imidazoline-2-base amino) quinoxaline, its salt and composition thereof one or more.
In one embodiment, chlorine oxygen component comprises the chlorite component.Described chlorine oxygen component can be stabilized chlorine dioxide or stable chlorine oxygen complex.
The amount of chlorine oxygen component can be about 1ppm of compositions to about 5000ppm, and for example about 10ppm is to about 1000ppm, or about 20ppm is to about 500ppm.Advantageously, the amount of chlorine oxygen component is higher than about 75ppm, and for example about 75ppm is above to about 500ppm or about 1000ppm or about 5000ppm.
In one embodiment, the borate component can include but not limited to boric acid, its salt (as borate) and composition thereof.The amount of borate component can be about 0.01% to about 10%, for example about 0.05% or about 0.1% to about 2% or about 5% (w/v) of compositions.In one embodiment, the amount of borate component is about 0.01% to about 3%.
In one embodiment, find to exist in the compositions of the present invention mannitol that the inhibitor effectiveness of compositions is produced illeffects.In a useful especially embodiment, compositions of the present invention does not comprise materials such as mannitol substantially, with this illeffects of basic elimination.
In one embodiment, compositions of the present invention comprises the glycerin component that exists with the amount that further effectively improves inhibitor effectiveness.The amount of glycerin component can effectively improve the inhibitor effectiveness that chlorine oxygen component or chlorine oxygen component combine with the borate component.Advantageously, for the essentially identical compositions of no glycerin component, comprise that the chlorine oxygen component of glycerin component or the inhibitor effectiveness of the present composition increase.Glycerin component can be included in the compositions that comprises the borate component.In addition, glycerin component also can be included in the compositions that does not comprise the borate component.
The present invention also provides and comprises aqueous components, oily components and treatment component, as the ophthalmic composition of quinoxaline component.In one embodiment, the pH value of aqueous components is controlled or adjustable, and make the treatment component effectively, produce required distribution as the quinoxaline component, for example so that most of, promptly about 50% or more, preferred about treatment component (quinoxaline component) more than 50% is positioned at aqueous components, as aqueous phase, or oily components, in oil phase.
The present invention also provides the treatment component (quinoxaline component) that makes in the ophthalmic composition to produce the method for required distribution.Described method can comprise sets or is adjusted into desirable value with the pH value of aqueous components that contains the compositions of aqueous components and non-aqueous component.
The pH of compositions can be about 3.0 to about 9.0, for example about 4.0 or about 5.0 to about 7.5 or about 8.5, or about 7.5 to about 8.0, for example about 7.9.
In one embodiment, distribute the treatment component so that about component more than 50% is arranged in aqueous components.For example, can distribute the treatment component so that about more than 60%, or about more than 70%, or about more than 80%, or about treatment component more than 90% is arranged in aqueous components.
Perhaps, also can distribute the treatment component so that about component more than 50% is arranged in oily components.For example, can distribute the treatment component so that about more than 60%, or about more than 70%, or about more than 80%, or about treatment component more than 90% is arranged in oily components.
In a useful embodiment, polyanionic (polyanionic) component that ophthalmic composition of the present invention comprises aqueous components, exist with the amount of effectively lubricating eye when the ocular administration compositions, the chlorine oxygen component that concentration is higher than about 75ppm and the borate component that exists with the amount of effective raising compositions inhibitor effectiveness for the essentially identical compositions of no borate component.
The various combinations of each feature of the present invention and two or more described features include within the scope of the invention, as long as the feature that is included in the described combination is not conflicting.
In following detailed description, embodiment and claim, above-mentioned and other aspect of the present invention and advantage are conspicuous.
The specific embodiment
The present invention relates to preserved ophthalmic compositions, the effect or the usefulness of antiseptic increase in for example described compositions.The present invention also relate to control or regulate treatment component in the ophthalmic composition the aqueous components of compositions and compositions such as the distribution between the non-aqueous component of oil phase.In one embodiment, compositions be used for to eye or the ophthalmic composition by the ocular delivery medicine, be used for the treatment of the eye drop of xerophthalmia ophthalmic composition, other is used to nurse ophthalmic composition of eye and nursing contact lens, described ophthalmic composition has benefited from anticorrosion.In certain embodiments, compositions of the present invention can be, for example artificial tears's compositions, wash lavation (irrigating) compositions of using in a compositions, the eye surgical operation or the like.
Compositions of the present invention advantageously is can eye usefulness; nontoxic substantially and/or non-stimulated and/or not damaged for example to eye; and can provide at least a benefit to the mankind or the animal of using compositions, for example can carry out Drug therapy (medication), can protect a cell and tissue or the like the mankind or animal.
The invention provides sneaking into of chloride oxygen preservative component.Preservative component can comprise one or more antiseptic.Useful antiseptic comprises the antiseptic that obtains antimicrobial acivity by chemistry or biochemical interaction with antibacterial or microorganism.
Preferably, chlorine oxygen component is present in the carrier component with safe concentration with concentration or eye that can eye usefulness, and aqueous carrier component for example is in liquid aqueous medium.
Selected chlorine oxygen component concentrations depends on, for example specific chlorine oxygen component killing bacteria, fungus and/or protozoacide or stop the effectiveness of its growth in anticorrosive composite.
According to the present invention, as the chlorine oxygen component that is highly profitable of antiseptic comprise hypochlorite component such as hypochlorite, such as the chlorate component of chlorate, such as the perchlorate component of perchlorate, and such as chloritic chlorite component.
Useful especially chlorine oxygen component comprises the chlorite component.The example of chlorite component includes but not limited to stabilized chlorine dioxide (SCD), such as metal chlorite such as alkalies and alkaline earth chlorite and composition thereof.The technical grade sodium chlorite is the chlorine oxygen component that is highly profitable.Definite chemical composition such as many chlorite components of SCD is not known as yet fully.The manufacturing of some chlorite component or the U.S.3 that produces at McNicholas state complete the including in this description of described patent mode by reference in 278,447.The instantiation of useful SCD product comprises Rio Linda Chemical Company, and the trade mark of Inc. is commercially available prod and the International Dioxide of Dura Klor, and the trade mark of Inc. is the commercially available prod of Anthium Dioxide.
With regard to another big aspect of the present invention, chlorine oxygen component to be to have the antiseptical of helping effective dose at least, for example makes that the effective antiseptical amount of one or more components is present in the compositions in the compositions.Preferably, chlorine oxygen component is to other component in the compositions, and the function such as the treatment component of quinoxaline component that for example is included in the compositions produces very big or remarkable adverse effect.
In one embodiment, adopt about 0.01ppm of concentration or higher chlorine oxygen component.For example, the employing amount of chlorine oxygen can be about 0.1ppm to about 4000ppm or about 5000ppm.In another example, the employing amount of chlorine oxygen can be about 0.1ppm to about 2000ppm or about 3000ppm.In another embodiment, the employing amount of chlorine oxygen can be about 0.1ppm or 1.0ppm to about 500ppm or about 1000ppm.In one embodiment, the amount of chlorine oxygen is that about 1.0ppm is to about 500ppm.
The very effective concentration of chlorine oxygen component is for being higher than about 75ppm in the present composition.This concentration is anticorrosion very effective for compositions, and not to other component generation illeffects of compositions, also the mankind or the animal of using compositions is not produced remarkable illeffects.The chlorine oxygen component of this concentration with borate component and/or the glycerin component that this description is stated in addition, can improve inhibitor effectiveness and the sufficiently long product shelf life (shelf life) is provided.Advantageously, the amount of chlorine oxygen component is above to about 2000ppm or about 3000ppm or about 5000ppm for about 75ppm.
A key character of the present invention is to comprise the borate component in the present composition.The borate component shows the effective raising to chlorine oxygen component effect in the ophthalmic composition of the present invention.For example, the borate component can improve the antibacterial activity and/or the antifungal activity of chlorine oxygen component in the ophthalmic composition.In one embodiment, for the essentially identical compositions of no borate component, the borate component has prolonged the shelf life of compositions.Useful borate component of the present invention includes but not limited to salt of boric acid, boric acid or the like and composition thereof.Example includes but not limited to Borax, sodium tetraborate, Dexol, ortho-boric acid, metaboric acid and composition thereof or the like.In addition, the present invention considers to use any suitable boron-containing compound, for example in the present composition, use can eye usefulness boron-containing compound, this boron-containing compound effectively improves the inhibitor effectiveness of the present composition.
Any amount that the borate component can effectively improve chlorine oxygen component effect in the compositions is present in the compositions.In one embodiment, the borate component concentrations that adopts in the compositions is about 0.001% (w/v) or higher.For example, the employing amount of borate component can be about 0.001% to about 10% (w/v) or about 20% (w/v).In another example, the employing amount of borate component can be about 0.005% to about 5% (w/v) or about 10% (w/v).In another embodiment, the employing amount of borate component can be about 0.005% or 0.01% to about 2% (w/v) or about 4% (w/v).Advantageously, the amount of borate component is about 0.01% to about 1% (w/v).
Another important aspect of the present invention is a glycerin component, such as but not limited to glycerol etc. and composition thereof, the effect that can improve chlorine oxygen component in the compositions.For example, when compositions also comprised the borate component, glycerin component can improve the effect of chlorine oxygen component in the compositions.Glycerin component in the compositions can be any amount of effective raising chlorine oxygen component effect.For example, glycerin component can improve the antibacterial activity and/or the antifungal activity of chlorine oxygen component in the compositions.In one embodiment, for the essentially identical compositions of no glycerin component, glycerin component has prolonged the shelf life of compositions.Glycerin component helps to improve the inhibitor effectiveness of the ophthalmic composition that comprises the emulsion with aqueous components and oily components very much.
In one embodiment, the concentration of the glycerin component that adopts in the compositions is about 0.001% (w/v) or higher.For example, the employing amount of glycerin component can be about 0.001% to about 30% (w/v).The employing amount of glycerin component can be about 0.005% or about 0.01% or about 0.1% to about 10% (w/v) or about 15% (w/v) or about 20% (w/v) or about 30% (w/v).Preferably, the amount of glycerin component is about 0.1% to about 5% (w/v).
Another importance of the present invention is that compositions of the present invention does not contain some saccharide and/or alcohols or sugar alcohol (being polyhydric alcohol) substantially.For example, compositions can not contain mannitol, Sorbitol, xylitol or the like and composition thereof substantially.In one embodiment, chlorine oxygen component is included in the compositions that does not contain one or more some saccharides, alcohols and/or polyhydric alcohol substantially, state in addition as this description, and with respect to comprising described material, the essentially identical compositions that for example comprises one or more saccharides, alcohols and/or the polyhydric alcohol of 1.5% (w/v), described chlorine oxygen component has one or more raising effects, the preferred inhibitor effectiveness that improves.In a useful especially embodiment, compositions does not contain mannitol substantially.
In one embodiment, for the essentially identical compositions that comprises 1.5% (w/v) mannitol, the inhibitor effectiveness that the present invention does not contain the compositions of mannitol substantially increases.In one embodiment, for the essentially identical compositions that comprises 1.5% (w/v) mannitol, the shelf life that does not contain the anticorrosive composite of mannitol substantially obtains prolonging.
Can comprise the treatment component in the compositions of the present invention.The example of useful treatment component includes but not limited to, nmda antagonist; Antibiotic substance, beta-Lactam antibiotic for example is as cefoxitin, positive formamido thiomycin and other thiomycin derivant, tetracycline, chloromycetin, neomycin, carbenicillin, colistin, benzylpenicillin, polymyxin B, vancomycin, cefazolin, cefaloridine, Chibro-rifamycin, Gramicidin, bacitracin and sulfa drugs; Aminoglycosides antibiotics, for example gentamycin, kanamycin, amikacin, sisomicin and tobramycin; Quinolinones, for example norfloxacin, ofloxacin or the like; Nitrofural and analog thereof; Hydryllin and Decongestant, for example neo-antergan, chlorphenamine, tetrahydrozoline (tetrahydrazoline), antazoline and analog thereof; Histamine release mastocyte inhibitor, for example cromoglicic acid etc.; Antiinflammatory, for example cortisone, hydrocortisone, hydrocortisone ester, betamethasone, dexamethasone, dexamethasone sodium phosphate, prednisone, methylprednisolone, medrysone, Cortilet, prednisolone, sodium phosphate prednisolone, omcilon, indomethacin (indainethacin), sulindac and analog thereof; Miotic and cholilytic drug, for example diethoxyphosphinylthiocholine, pilocarpine, physostigmine salicylate, isoflurophate, epinephrine, two pivaloyl epinephrines, iodate diethoxyphosphinylthiocholine neostigmine, demecarium bromide, carbachol, methacholine, bethanechol chloride and analog thereof; Iridodilator, for example atropine, melyltropeine, scopolamine, oxamphetamine, ephedrine, cocaine, N-ethyl-N-(.gamma.-picolyl)tropamide, phyenlephrinium, cyclopentolate, oxyphenonium Bromide, eucatropine; Material like that and composition thereof.
Other treatment component includes but not limited to: Betimol, the conjugate (combination) of for example timolol, particularly its maleate and R-timolol, and timolol, timolol maleate and/or R-timolol and pilocarpine; Adrenergic agonist and/or antagonist, for example epinephrine and epinephrine coordination compound, and prodrug, for example biatrate, borate, hydrochloride and dipivefrine derivant; Carbonic anhydrase inhibitors, for example acetazolamide, dichlorphenamidum, 2-are to hydroxyphenyl-sulfo-thiophene-sulfonamide, 6-hydroxyl-2-[4-morpholinodithio sulfonamide and 6-new pentane acyloxy-2-[4-morpholinodithio sulfonamide; Anti-parasitic chemical compound and/or protozoacide chemical compound, for example ivermectin, the pyridine of breath malaria, neotrizine (trisulfapidimidine), clindamycin and corticosteroid goods; Chemical compound with antiviral activity, for example acycloguanosine, 5-iodo-2 '-uracil deoxyriboside (IDU), vidarabine (Ara-A), trifluridine, interferon and such as the interferon inducers of polyinosini; Antifungal, for example joint silk mycin B, nystatin, flucytosine, Baunatal mycin and miconazole; Anesthetis, for example etidocaine cocaine, benoxinate, quinocaine, dyclonine hydrochloride, naepaine, phenacaine hydrochloride, piperocaine, proparacaine hydrochloride, tetracaine hydrochloride, hexylcaine, bupivacaine, lignocaine, mepivacaine and prilocaine; The eye diagnostic agent, for example: (a) be used to check amphiblestroid diagnostic agent, fluorescein sodium for example, (b) be used to check the diagnostic agent of conjunctiva, cornea and lacrimal apparatus, fluorescein and rose-red for example, reach the diagnostic agent that (c) is used to check unusual pupillary reaction, for example methacholine, cocaine, epinephrine, atropine, oxamphetamine and pilocarpine; In surgical operation, be used as eye reagent, for example Chymetin and the hyaluronidase of adjuvant; Chelating agen, for example ethylenediaminetetraacetic acid (EDTA), its salt and deferoxamine; Immunosuppressant and antimetabolite, for example methotrexate, cyclophosphamide, Ismipur and azathioprine; And the conjugate of mentioned reagent, for example antibacterial/antiinflammatory conjugate as the conjugate of polygynax and dexamethasone sodium phosphate, and is used for the treatment of glaucomatous conjugate, for example the conjugate of timolol maleate and aceclidine jointly; Material like that and composition thereof.
Other useful treatment component comprises such as people such as Woodward at U.S.5, disclosed ocular hypotensive agent in 688,819; Such as people such as Cairns at U.S.4, disclosed pyrans and quinoline (pyranoquinolinone) derivant in 474,787; At U.S.5, disclosed in 089,509 have an active chemical compound of biostearin such as Chandraratna; Such as people such as Muchowski at U.S.4, disclosed ketorolac/pyrroles-1-carboxylic acid in 089,969; Such as people such as Hayakawa at U.S.4, disclosed ofloxacin/benzo-oxazine derivative in 382,892; And people such as Lipton is at U.S.5, disclosed Memantine hydrochloride in 922,773.Patent U.S.5,688,819,4,474,787,5,089,509,4,089,969,4,382,892 and 5,922, complete the including in this description of 773 disclosure mode by reference.
In a useful embodiment, treatment component of the present invention comprises the adrenergic agonist.Described epinephrine agonist can be pKa greater than about 7, the chemical individual that contain amine of for example about 7 (or greater than about 7) to about 9.
In one embodiment, useful treatment component comprises the alpha-adrenergic agonist.The example of alpha-adrenergic agonist includes but not limited to, adrafinil, Adrenalone (adrenolone), amidefrine, Apraclonidine, budralazine 1,4-Benzodiazine, clonidine, cyclopentamine, detomidine, dimetofrine, dipivefrine, ephedrine, epinephrine, Fenoxazoline, that benzyl of croak, croak method suffering, oxamphetamine, ibopamine, Farial, isometheptene, mephentermine, aramine, methoxamine, 2-amino-4-methylhexane, Benazoline (metizolene), the midodrine, naphazoline, norepinephrine, norfenefrine, octodrine, norsympatol, oxymetazoline, phenylephrine, benzyl alcohol amine, phenpromethamine, veritol, eventin, pseudoephedrine, rilmenidine, adrianol, tetrahydrozoline, tiamenidine, tramazoline, tuaminoheptane, tymazoline, tyramine, xylometazoline or the like and composition thereof.
In a useful embodiment, the treatment component comprises α-2-adrenergic agonist.The used term " α-2-adrenergic agonist " of this description comprises chemical individual, for example chemical compound, ion, coordination compound etc., described chemical individual can by for example with joint back SNE on presynaptic α-2 receptors bind, or produce final sympatholytic reaction, thereby cause that modulability (accommodation) strengthens with postsynaptic α-2 receptors bind on the smooth muscle cell for example.The sympatholytic reaction is characterised in that inhibition, reduces or stops the impulse action that transmits by sympathetic nervous system.α of the present invention-2-adrenergic agonist can combine with α-2-adrenoreceptor presynaptic, caused that negative feedback is to reduce the release of neuronal norepinephrine.In addition, the postsynaptic effect also can take place with α-2-adrenoreceptor in described α-2-adrenergic agonist, suppress B-adrenergic receptor and be excited to form cyclic adenosine monophosphate, the postsynaptic α-2-adrenoreceptor effect of this effect on other cell internal channel causes ciliary muscle relaxation.No matter presynaptic α-2-adrenoreceptor still is postsynaptic α-2-adrenoceptor, and its activity all can cause Adrenergic influence to reduce.The contraction that the reduction of adrenergic influence causes being caused by cholinergic innervation strengthens.α-2-adrenergic agonist also comprises the chemical compound with neuroprotective activity.For example, quinoxaline is exactly a kind of α-2-adrenergic agonist with neuroprotective activity to 5-bromo-6-(2-imidazoline-2-base is amino), but its mechanism of action is not known as yet.
Listed below and be used for representative α of the present invention-2-adrenergic agonist, but the present invention is not limited to listed concrete kind and chemical compound: iminoimidazoline comprises clonidine, Apraclonidine; Imidazoline comprises naphazoline, xylometazoline (xymetazoline), tetrahydrozoline and tramazoline; Imidazoles comprises detomidine, medetomidine and dexmedetomidine; Azepines comprises B-HT 920 (6-pi-allyl-2-amino-5,6,7,8 tetrahydrochysenes-4H-thiazole [4,5-d]-azepines) and B-HT 933; Thiazine comprises the methylbenzyl thiazine; Oxazolidine comprises rilmenidine; Guanidine comprises that benzyl of croak and croak method suffering; Catecholamine or the like.
Useful especially α-2-adrenergic agonist comprises the quinoxaline component.In one embodiment, the quinoxaline component comprises quinoxaline, its derivant and composition thereof.Quinoxaline derivant includes but not limited to (2-imidazoline-2-base is amino) quinoxaline, its salt and composition thereof.In one embodiment, quinoxaline derivant comprises 5-halogen-6-(2-imidazoline-2-base is amino) quinoxaline, its salt and composition thereof." halogen " of 5-halogen-6-(2-imidazoline-2-base is amino) quinoxaline can be fluorine, chlorine, iodine, or preferred bromine, to form 5-bromo-6-(2-imidazoline-2-base the is amino) quinoxaline (brimonidine) that also is called as brimonidine.
Quinoxaline that other is useful and quinoxaline derivant are known.For example, useful quinoxaline and quinoxaline derivant comprise U.S.5, disclosed quinoxaline and quinoxaline derivant in 021,416,5,703,077 and 3,890,319.Complete the including in this description of the disclosure of described three parts of patents mode by reference.
The quinoxaline derivant that quinoxaline reaches such as brimonidine contains amine, and preferred pKa value is greater than about 7, preferred about 7.5 to about 9.
Also special consider as the material of the treatment component of the present composition be: work with the analog of aforementioned chemical individual that the expection therapeutic effect is provided, salt (as salt that can eye usefulness) and other derivants by similar mode.
In a useful embodiment, the amount of treatment component is about 0.01% to about 30% (w/v) in the present composition.The amount of treatment component can be about 0.1% (w/v) to about 10% (w/v).For example, the amount of treatment component can be about 0.1% (w/v) to about 0.6% (w/v).In one embodiment, the treatment component is the adrenergic agonist, and its amount in compositions is that about 0.1% (w/v) is to about 0.6% (w/v), for example about 0.15% (w/v).
Compositions of the present invention can be solution or the suspension in waterborne liquid or the non-aqueous liquid easily, or is oil-in-water or water in oil liquid emulsion.Compositions of the present invention can comprise conventional one or more compositions that adopt in the same big based composition.
The compositions of waterborne suspension form of the present invention can comprise the excipient that is suitable for preparing waterborne suspension.Described excipient includes but not limited to suspending agent, for example Sodium Tvlose, methylcellulose, hydroxypropyl emthylcellulose, sodium alginate, polyvinylpyrrolidone, Tragacanth (guntragacanth) and arabic gum (gun acacia); Dispersant or wetting agent can be naturally occurring phospholipid, for example lecithin, or the condensation product of oxirane and long chain aliphatic, 17 ethyleneoxy hexadecanol for example, or oxirane and derived from the condensation product of the partial ester of fatty acid and hexitol, octadecanoic acid ester of polyethylene glycol for example, or oxirane and derived from the condensation product of the partial ester of fatty acid and dewatering hexitol, the single oleic acid of polyoxyethylene sorbitol for example, material like that and composition thereof.
The compositions of oily suspensions form of the present invention can be prepared in following material: vegetable oil, for example olive oil, Oleum Ricini, soybean oil, Oleum sesami or Oleum Cocois; Or mineral oil, for example liquid paraffin.Described suspension can comprise thickening agent, for example Cera Flava, hard paraffin or spermol.
Compositions of the present invention can be the O/w emulsion form.Oil phase can be vegetable oil, for example Oleum Ricini, olive oil, soybean oil or Oleum Arachidis hypogaeae semen; Or mineral oil, for example liquid paraffin; Material like that and composition thereof.The emulsifying agent that is fit to can be naturally occurring natural gum, for example Radix Acaciae senegalis or Tragacanth; Naturally occurring phospholipid, for example soybean lecithin; Derived from the ester or the partial ester of fatty acid and dewatering hexitol, for example sorbitol monooleate; And the condensation product of described partial ester and oxirane, for example octadecanoic acid ester of polyethylene glycol.
Can be used for the oil/aqueous emulsion that is highly profitable of the present invention states in the U.S. Patent Application Serial Number 10/349,466 of the common transfer of submission on January 22nd, 2003.Complete the including in this description of the disclosure of above-mentioned application mode by reference.
In a useful embodiment, the invention provides the distribution of treatment component in the compositions.In described embodiment, compositions comprises that two or more phases can be for distributing the treatment component.For example, compositions can comprise that the water component reaches the nonaqueous phase component such as oil phase, and can be O/w emulsion or Water-In-Oil liquid emulsion form.The part (or percentage ratio) that treatment component in the assign group compound is meant whole treatment components is mutually or in heterogeneous of compositions.For example, the first of treatment component can one of compositions mutually in (for example aqueous components or such as the non-aqueous component of oily components), and remaining treatment component compositions other mutually in.
The distribution that an importance of the present invention relates to one or more therapeutic agents can be determined by the pH value of water component in the compositions.
Limit under the prerequisite of the present invention with any theory of operation not intending, think that the treatment component can be used as charged species or free radical (free base) or its conjugate and exists.For example, near 8.0, for example pH is that 7.9 o'clock forms with free radical exist to most of treatment component (for example brimonidine) at pH.The treatment component of radical form, its hydrophobicity it is believed that stronger than charged treatment component, so the treatment component of radical form compares with charged treatment component, are easier to be dispensed in the oily components of compositions.In addition, some hydrophobicity treatment component it is believed that the treatment component more weak than hydrophobicity is easier to see through cornea.
In one embodiment, advantageously treat the part of component in oily components many than in aqueous components.In another embodiment, advantageously treat the part of component in aqueous components many than in oily components.In another embodiment, advantageously treat the part of component in aqueous components basic identical with in oily components.In a useful embodiment, treatment component (for example brimonidine) can be present in and comprise that pH is in the ophthalmic composition of about 7.9 aqueous components, and for the lower essentially identical compositions of pH value, under this pH value, the treatment component can exist as free radical more.
The pH value of compositions can make the whole treatment components in the compositions be present in the specific phase of compositions with arbitrary proportion.For example, pH value can be about pH5.0 to about pH10.0, or about pH5.5 is to about pH9.5, or about pH6.0 about pH9.0 extremely, or about pH6.5 to pH8.5, or about pH7.0 about pH8.0 extremely.
In one embodiment, first in compositions treatment component can be dispensed to one of compositions mutually in and the treatment of second in compositions component is dispensed to compositions another mutually in.
For example, limit under the prerequisite of the present invention with any theory of operation not intending, think some O/w emulsion compositions or water-in-oil emulsion composition, at pH value is about 6.5 o'clock, and the treatment component such as brimonidine of (for example about more than 99%) more than 90% of having an appointment is dispensed to the aqueous components or the aqueous phase of compositions.And similar compositions is about 8.0 o'clock at pH value, and 50% the treatment component such as brimonidine of having an appointment is dispensed in the oil phase or oily components of compositions.
The carrier component of the present composition is can eye usefulness.Carrier component or other materials are when be " can eye usefulness " when compatible substantially with ocular tissue.That is, when it contacts with ocular tissue, do not produce significant or unsuitable harmful effect.Preferably, can the eye usefulness material also compatible substantially with other components of the present composition.Carrier component can comprise that one or more effectively provide can be of value to compositions and/or use the eye of compositions and/or eye patient's to be treated component with the component of property and/or other by eye.Advantageously, carrier component be contain water base, for example, comprise a large amount of, promptly at least about the water of 50% weight.
The example that can be used for the suitable material of carrier component of the present invention comprises the mixture of water, water and water-miscible solvent, described water-miscible solvent for example low-level chain triacontanol or aralkyl alcohol, oily components, vegetable oil, Polyethylene Glycol, mineral jelly, ethyl cellulose, ethyl oleate, polyvinylpyrrolidone, myristic acid isopropyl esters (isopropyl mirstate), other conventional adopt can eye with material or the like and composition thereof.
Carrier component also can comprise auxiliary substance, for example emulsifying agent, wetting agent, thickening agent, buffer components, acid and/or alkali, tension regulator component, surface active agent composition, viscosity modifier, lubricant composition, preservative component, other is used for the material etc. of ophthalmic preparation, includes but not limited to the conventional described material that uses in the ophthalmic composition.
The example that can choose the thickening agent of use wantonly includes but not limited to, multiple Polyethylene Glycol, carbowax, mineral jelly etc.
The buffer agent that is fit to includes but not limited to, inorganic buffer agent, for example phosphate buffer, borate buffer etc., and organic buffer agent, for example acetate buffer, citrate buffer agent, trometamol etc.
Can choose the tension regulator that is used for the present composition wantonly and include but not limited to, dextrose, potassium chloride and/or sodium chloride etc., preferred sodium chloride.
Can choose the acid that is used for the present composition wantonly and comprise, boric acid, hydrochloric acid, acetic acid, other is acid that can eye usefulness or the like in institute's working concentration.
The alkali that can be included in the present composition includes but not limited to, sodium hydroxide and/or potassium hydroxide, other alkali metal hydroxide and/or alkaline earth metal hydroxide, organic base, other is alkali that can eye usefulness or the like in institute's working concentration.
If comprise acid/alkali/buffer agent, preferably they make and/or the pH value that keeps the present composition in physiologically acceptable scope, more preferably from about 4 to about 8.5, further preferred about 6 to about 8, especially preferred about 6.8 to about 8.
Can choose the surface active agent composition that is used for the present composition wantonly and include but not limited to the lipoprotein detergent, when it is present in the compositions, will reduce the surface tension between compositions and eye (tear) liquid.The preferred non-ionic surface active agent that uses.
Can choose the viscosity agent that is used for the present composition wantonly and include but not limited to, cellulose derivative, for example useful viscosity inductive substance or the like in hydroxypropyl emthylcellulose, carboxymethyl cellulose, hydroxyethyl-cellulose, other ophthalmic preparation.
In an embodiment that is highly profitable, compositions of the present invention comprises polyanionic component.Advantageously, polyanionic component exists with the amount of effectively lubricating eye when the ocular administration compositions.The amount of polyanionic component be generally compositions at least about 0.1%w/v.For example, the amount of polyanionic component can be about 0.1% or about 0.2% to about 1% (w/v) or 5% (w/v) or about 10% (w/v) of compositions.In another example, the amount of polyanionic component be compositions about 0.6% to about 1.8% (w/v).
Any suitable polyanionic component all can adopt according to the present invention, as long as its effect as described in this manual, and generally compositions or the eye of using compositions is not had harmful effect substantially.Described polyanionic component should be under the concentration that eye is suitable for can eye usefulness, with other component compatibility of compositions and be effective, so that promote will be such as the treatment component applied of quinoxaline to eye, and realize other effect of the present invention when being applied to eye.
As used in this description, term " polyanionic component " " refer to a kind of chemical individual, for example ionic charged kind, for example ionic charged polymer; and described ionic charged polymer comprises more than one discrete (discrete) anionic charge, promptly a plurality of discrete anionic charges.Preferably, polyanionic component is selected from polymer that has a plurality of anionic charges and composition thereof.
The example that can be used for the polyanionic component that is fit to of the present composition includes but not limited to, anionic cellulose derivant, anion contain that acrylate copolymer, anion contain methacrylate polymer, anion contains amino acid polymer or the like and composition thereof.The anionic cellulose derivant is useful especially in the present invention.
The polyanionic component that one class is highly profitable is one or more polymer with a plurality of anionic charges.Example includes but not limited to:
The metal carboxymethyl cellulose
The metal carboxymethyl hydroxyethyl cellulose
The metal carboxymethyl starch
Metal carboxymethyl hetastarch
The methylcellulose ammonium
The methylcellulose amino-compound
Hydrolyzed polyacrylamide and polyacrylonitrile
Heparin
gucoaminoglycan
Hyaluronic acid
Chondroitin sulfate
Dermatan sulfate
Peptide and polypeptide
Alginic acid
The alginic acid slaine
The homopolymer of following material and one or more copolymer:
Acrylic acid and methacrylic acid
Acrylate metal salt and metering system acid metal salt
Vinyl sulfonic acid
The vinyl sulfonic acid slaine
Aminoacid, for example aspartic acid, glutamic acid etc.
Amino acids metal salt
P styrene sulfonic acid
The p styrene sulfonic acid slaine
2-isobutene. acyl-oxygen base ethylsulfonic acid
2-isobutene. acyl-oxygen base ethylsulfonic acid slaine
3-isobutene. acyl-oxygen base-2-hydroxypropyl sulfonic acid
3-isobutene. acyl-oxygen base-2-hydroxypropyl metal organic sulfonate
2-acrylamido-2-methyl propane sulfonic acid
2-acrylamido-2-methyl propane sulfonic acid slaine
Allyl sulphonic acid
Allyl sulphonic acid slaine or the like.
Use is selected from carboxymethyl cellulose and composition thereof, and for example the polyanionic component of alkali metal and/or alkaline-earth metal carboxymethyl cellulose can obtain fabulous result.
In one embodiment, polyanionic component comprises the polyanionic component part more than, and the molecular weight of each polyanionic component part is different with the polyanionic component part that other constitutes polyanionic component.
In an embodiment that is highly profitable, polyanionic component comprises first polyanionic component part with first molecular weight and has the second polyanionic component part of second molecular weight.In one embodiment, the amount of each polyanionic component part be compositions at least about 0.01%w/v.For example, the amount of each polyanionic component part can be about 0.01% or about 0.1% or about 0.2% or about 2% (w/v) or about 5% (w/v) or about 10% (w/v) of compositions.In another example, the amount of each polyanionic component part be compositions about 0.1% to about 2.0% (w/v).
As above mentioned, each polyanionic component part can have different molecular weight.In one embodiment, second molecular weight of first molecular weight ratio, second polyanionic component part of first polyanionic component part is big.Between the polyanionic component part, for example the difference of molecular weight between first and second polyanionic component part can be at least about 10,000, for example at least about 50,000.
In one embodiment, first polyanionic component part is about 0.02 to about 50 with the weight ratio of second polyanionic component part.For example, first polyanionic component part is about 0.25 to about 4 with the weight ratio of second polyanionic component part.
Use as this description, term " molecular weight " refers to weight average molecular weight, and term is known in polymer arts as described, and described molecular weight can use method well known in the art and/or technology to measure or determine.
In a useful embodiment, at least one polyanionic component partly is selected from anionic cellulose derivant and composition thereof.In the embodiment that is highly profitable, all polyanionic component partly is selected from carboxymethyl cellulose and composition thereof.
The polyanionic component that also can adopt other to be fit to.For example, at least one, for example all the polyanionic component part can be selected from unitary anionic homopolymers and the copolymer that comprises one or more acrylic acid, methacrylic acid, acrylate metal salt, metering system acid metal salt and composition thereof.The polyanionic component that is highly profitable that can be elected to be at least one first and second polyanionic component part is unitary homopolymer and the copolymer that comprises one or more acrylic acid, acrylate metal salt and composition thereof.Polyanionic component can comprise three (3) individual or more aniones (or negative) electric charge.When polyanionic component was polymer, each repetitive of preferred polymers comprised discrete anionic charge.Useful especially anionic group is divided into the water-soluble anionic component, for example under ambient temperature (room temperature) with the present composition in used concentration be soluble.
Each polyanionic component part can have different molecular weight.In an embodiment that is highly profitable, polyanionic component comprises first polyanionic component part with first molecular weight and has second polyanionic component of second molecular weight.Advantageously, the amount of each polyanionic component part will effectively promote to be applied to ophthalmic such as the treatment component of quinoxaline component by cornea when compositions is applied to eye.The amount of each polyanionic component part can be compositions at least about 0.1%w/v.
In one embodiment, at least two polyanionic component parts, first and second polyanionic component part for example, except that the molecular weight difference, its chemical constitution is similar substantially.Yet the chemical constitution of at least two polyanionic component parts also can be different.
Can obtain each polyanionic component part respectively, for example first and second polyanionic component part.In other words, each polyanionic component part can be bonded in the compositions of the present invention as independent material.
The viscosity of the present composition preferably is higher than the viscosity of water.In one embodiment, the viscosity of the present composition is at least about 15cps (centipoise), and for example about 15cps is to about 2000cps or about 3000cps.Advantageously, the viscosity of the present composition can be about 30cps or about 70cps to about 750cps or about 1000cps.In one embodiment, the viscosity of compositions is about 15cps or about 50cps about 200cps extremely.In another embodiment, the viscosity of compositions for about 30cps to about 5000cps or about 200cps about 4000cps extremely.In another embodiment, the viscosity of compositions is that about 200cps is to about 2000cps.
Viscosity can per second 1 to 10 shear rate measure.The viscosity of the present composition can be measured in any suitable manner.Conventional Brookfield viscometer can be used for measuring described viscosity.Compositions both can be newton's compositions and also can be the non newtonian compositions.The shear thinning characteristic of non newtonian compositions can make it have lower viscosity under physics shearing (as fold (blinking)) condition, therefore, can make the initial viscosity of non newtonian compositions be higher than newton's compositions.
As mentioned before, each polyanionic component part, that is, and first and second polyanionic composition component part at least for example, its amount can be compositions at least about 0.1% (w/v).In an embodiment that is highly profitable, the amount of polyanionic component be compositions about 0.2% to about 5%, for example about 0.4% to about 2.5%, or for example about 0.6% to about 1.8%, or for example about 0.8% to about 1.3% (w/v).
First polyanionic component part can change in relative broad range with the weight ratio of second polyanionic component part.In one embodiment, the weight ratio of first and second portion is about 0.02 to about 50, and preferred about 0.1 to about 10, more preferably from about 0.25 to about 4.
Can obtain the different polyanionic component part of the present composition respectively, for example first and second polyanionic component part.In other words, can different (for example first and second) polyanionic component of separate sources is partially mixed to compositions of the present invention.The molecular weight difference of different polyanionic component parts can be at least about 10,000, for example at least about 50,000.
In a useful embodiment, polyanionic component further comprises the 3rd polyanionic component part with three molecular weight different with first and second molecular weight.Preferably, for the essentially identical compositions of no third polymers compositions part, the amount of the 3rd polyanionic component part will effectively promote treatment component applied such as the brimonidine component to eye.
What be included in the scope of the present invention is applied to the corrosion preventive compound that its viscosity improves behind the eye in addition.For example, U.S.5, in 212,162 disclosed " gelling polysaccharide ", complete this description of including in of described patent mode by reference.Described patent also discloses the ophthalmic preparation that comprises carrageenan and furcellaran, is the agglomerative liquid of part when described ophthalmic preparation is used, and gelling promptly takes place after splashing into ophthalmic.In addition, U.S.4,136,173,4,136,177 and 4,136,178 also disclose the purposes of the therapeutic combination that comprises xanthan gum and carob gum, and gelling to ocular delivery, and takes place with the form of liquid in described therapeutic combination when instiling.U.S.4,861,760 disclose the ophthalmic composition that comprises gellan gum, and described ophthalmic composition is not agglomerative liquid when ocular administration, and when instiling gelling takes place.Whole complete the including in this description of mode by reference of the disclosure of described four parts of patents.
What be included in the scope of the present invention also has anticorrosion grease, ointment, gel or the like.Compositions of the present invention can comprise, cyclodextrin composition for example is included in the dissolubility of one or more other components in the compositions with raising.For example, the water solublity of hydrophobic steroid showed an order of magnitude or more increasing usually under cyclodextrin existed.Any suitable cyclodextrin composition all can adopt according to the present invention.Useful cyclodextrin composition includes but not limited to, effectively improve the apparent solubility of poorly soluble active component, preferred improve its water miscible cyclodextrin material, and/or improve the stability of described active component and/or reduce the harmful side effect of described active component.The example of useful cyclodextrin composition includes but not limited to: alpha-cyclodextrin, the derivant of alpha-cyclodextrin, beta-schardinger dextrin-, the derivant of beta-schardinger dextrin-, gamma-cyclodextrin, the derivant of gamma-cyclodextrin, carboxymethyl-beta-cyclodextrin, carboxymethyl-ethyl-beta-schardinger dextrin-, DE-, DM-, methyl-beta-schardinger dextrin-, random methyl-beta-schardinger dextrin-, the glucose group-beta-cyclodextrin, malt sugar group-beta-cyclodextrin, hydroxyethyl-, HP-, sulfobutyl ether-beta-cyclodextrin or the like and composition thereof.As used in this description, term " derivant ", when it relates to cyclodextrin, be meant the feature chemical constitution with cyclodextrin, the chemical compound any replacement or that otherwise modify that is enough to be used as cyclodextrin composition, for example, with dissolubility and/or the stability that improves active component and/or the harmful side effect that reduces active component and/or to form inclusion complex (inclusive complex), as described in this manual with active component.
The present composition also can comprise one or more other components according to its concrete application.For example compositions of the present invention can be formulated as and comprise the treatment component that is applied to eye.
Can be to ocular administration anticorrosive composite of the present invention.Suitably the described compositions of preparation can be used for replacing the compositions of this area routine.For example, described compositions can be used for to ocular administration treatment component.In one embodiment, a kind of antibiotic administration in the present composition is to eye.In another embodiment, compositions of the present invention can be used as the surgical operation irrigating.
Compositions of the present invention also can be used in the contact lens care, for example, so that the safe wearing of eyeglass and comfortable.By compositions of the present invention being replaced the compositions of this area routine, the present composition of suitably preparing can be used for conventional contact lens care scheme.As a rule, described contact lens care scheme comprises eyeglass is contacted with a certain amount of present composition to obtain useful or required contact lens care effect.
Following non-restrictive example explanation some aspect of the present invention.
Each preparation that proposes in following examples all mixes listed component by conventional methods and prepares.
The inhibitor effectiveness that various described preparations have all carried out simplifying is tested, and the mensuration bacterium of using in the test is staphylococcus aureus (S.aureus), bacillus pyocyaneus (p.aeruginosa), Candida albicans (c.albicans), escherichia coli (E.coli) and/or aspergillus niger (A.niger).The test of preparation according to the test of specified U.S. inhibitor effectiveness (Preservative EfficacyTest, USP), European effect test-A (Efficacy Test-A, EP-A) and European effect test-B (Efficacy Test-B, EP-B) standard is carried out.Every kind of preparation uses about 10 for each ten (10) milliliters
5The test bacterium of cfu/ml is tested.At reasonable time at interval, use DeyEngley culture medium (DE) as nertralizer (neutralizer) medium bacterial detection and fungi surviving amount.DE and filtration are enough to the antimicrobial in the neutralization composition.Every kind of sample is diluted among nine (9) milliliters of DE for each one (1) milliliter.One (1) milliliter of diluent of 1: 10 filters by the filter of 0.45 μ m, and with 100ml saline/polyoxyethylene sorbitan monoleate solution washing.After 100ml saline/polyoxyethylene sorbitan monoleate solution secondary washing filter liquor, filtrate is placed bacterial detection on the TSA plate, and on the SAB plate, detect fungus.
Embodiment 1
Preparation is planted in preparation and test following four (4).Measurement result is summarized as follows:
| Component | Preparation 1 | Preparation 2 | Preparation 3 | Preparation 4 |
| Pemulen TR-2(1) ％(w/v) | 0.05 | |||
| Polyoxyethylene sorbitan monoleate % (w/v) | 1 | |||
| Oleum Ricini % (w/v) | 1.25 | |||
| Boric acid % (w/v) | - | |||
| Mannitol % (w/v) | - | |||
| Glycerol % (w/v) | 2.2 | |||
| PH | 7.4 | |||
| Purify waste water | QS 100％ | |||
| Chlorine oxygen component (2) (ppm) | 0 | 25 | 50 | 150 |
| USP | By bacillus pyocyaneus 0.6log reduction/7 days escherichia coli 0.2 log reduction/7 day | By | By | By |
| EP-B | By staphylococcus aureus 0log reduction/24 hours Pseudomonas aeruginosa 0log reduction/24 hours Candida albicans 0log reduction/14 days aspergillus niger 0.3log reduction/14 days | By Candida albicans 0.2log reduction/14 days aspergillus niger 0.3log reduction/14 days | By Candida albicans 0.4log reduction/14 days aspergillus niger 0.4log reduction/14 days | By |
| EP-A | By staphylococcus aureus 0log reduction/6 hours Pseudomonas aeruginosa 0.3log reduction/6 hours Candida albicans 0.2log reduction/7 days aspergillus niger 0log reduction/7 days | By staphylococcus aureus 0.6log reduction/6 hours Candida albicans 0.2log reduction/7 days aspergillus niger 0.2log reduction/7 days | By staphylococcus aureus 1.2log reduction/6 hours Candida albicans 0.4log reduction/7 days aspergillus niger 0.3log reduction/7 days | By Candida albicans 0.7log reduction/7 days aspergillus niger 0.8log reduction/7 days |
(1) the alkyl acidylate cross linked polymer of C10 to C30
(2) stabilized chlorine dioxide, by (the Allergan of Allergan Inc, Inc.) provide this embodiment to show, in some cases chlorine oxygen component can not effectively be satisfied some inhibitor effectiveness standard, for example European effect test-A (EP-A) or European effect test-B (EP-B) as antiseptic.Preparation 1 to 4 does not comprise boric acid.
Embodiment 2
Preparation is also tested another kind of preparation, preparation 5.As follows with preparation 4 measurement result relatively:
| Component | Preparation 4 | Preparation 5 |
| Chlorine oxygen component (2) (ppm) | 150 | |
| Pemulen TR-2(1) ％(w/v) | 0.05 | |
| Polyoxyethylene sorbitan monoleate % (w/v) | 1 | |
| Oleum Ricini % (w/v) | 1.25 | |
| Purify waste water | QS 100％ | |
| Boric acid % (w/v) | - | 0.15 |
| Mannitol % (w/v) | - | 1.5 |
| Glycerol | 2.2 | 1 |
| ％(w/v) | ||
| PH | 7.4 | 7.3 |
| USP | By | By |
| EP-B | By | By |
| EP-A | By Candida albicans 0.7log reduction/7 days aspergillus niger 0.8log reduction/7 days | By Candida albicans 0.5log reduction/7 days aspergillus niger 0.9log reduction/7 days |
This embodiment shows, exists the boric acid of mannitol and low concentration substantially the inhibitor effectiveness of compositions not to be had any effect simultaneously.For example, when preparation 4 is compared with the preparation 5 that comprises 0.15% (w/v) boric acid and 1% (w/v) mannitol, show two kinds of preparations all by USP and EP-B, but do not pass through EP-A.
Embodiment 3
Prepare in addition and test two kinds of preparations.Measurement result is summarized as follows:
| Component | Preparation 6 | Preparation 7 |
| Chlorine oxygen component (2) (ppm) | 50 | |
| Pemulen TR-2(1) ％(w/v) | 0.05 | |
| Oleum Ricini % (w/v) | 1.25 | |
| Mannitol % (w/v) | - | |
| PH | 7.4 | |
| Purify waste water | QS 100％ | |
| Polyoxyethylene sorbitan monoleate % (w/v) | 1 | 0.8 |
| Boric acid % (w/v) | - | 0.2 |
| Glycerol % (w/v) | 2.2 | 1 |
| USP | By | By |
| EP-B | Not by Candida albicans 0.4log reduction/14 days aspergillus nigers | By |
| 0.4log reduction/14 day | ||
| EP-A | By staphylococcus aureus 1.2log reduction/6 hours Candida albicans 0.4log reduction/7 days aspergillus niger 0.3log reduction/7 days | By aspergillus niger 0.7log reduction/7 days |
This embodiment shows, during no mannitol, even have only a spot of boric acid, also can improve the inhibitor effectiveness of preparation 7 with chlorine oxygen component in the preparation.Therefore, the preparation 6 that does not comprise boric acid is by EP-A and EP-B testing standard, and the preparation 7 that comprises 0.2% (w/v) boric acid is by the EP-B testing standard.
Embodiment 4
Preparation and test be two kinds of preparations in addition.Measurement result is summarized as follows:
| Component | Preparation 8 | Preparation 9 |
| Chlorine oxygen component (2) (ppm) | 150 | |
| Pemulen TR-2(1) ％(w/v) | 0.1 | |
| Polyoxyethylene sorbitan monoleate % (w/v) | 1 | |
| Oleum Ricini % (w/v) | 1.25 | |
| Glycerol % (w/v) | 1 | |
| PH | 7.3 | |
| Purify waste water | QS 100％ | |
| Boric acid % (w/v) | 0.15 | 0.6 |
| Mannitol % (w/v) | 1.5 | - |
| USP | By | By |
| EP-B | By aspergillus niger 0.2log reduction/14 days | By |
| EP-A | Do not pass through | By |
| Candida albicans 0.2log reduction/14 days aspergillus niger 0.1log reduction/14 days |
This embodiment shows, for example uses that concentration is the boric acid of 0.6% (w/v), and when not having mannitol, the antiseptic property of the preparation of chloride oxygen component significantly improves.Preparation 9 is by whole USP, EP-A and EP-B testing standard.On the contrary, preparation 8 is only by the USP testing standard.
Embodiment 5
Preparation and test be two kinds of preparations in addition.Measurement result is summarized as follows:
| Component | Preparation 10 | Preparation 11 |
| Chlorine oxygen component (2) (ppm) | 25 | 25 |
| Pemulen TR-2(1) ％(w/v) | - | 0.1 |
| Polyoxyethylene sorbitan monoleate % (w/v) | - | 1 |
| Oleum Ricini % (w/v) | - | 1.25 |
| Glycerol % (w/v) | - | 1 |
| PH | 7.3 | 7.3 |
| Purify waste water | QS 100％ | QS 100％ |
| Boric acid % (w/v) | 0.6 | 0.6 |
| Sodium chloride % (w/v) | 0.3 | - |
| USP | Do not carry out | By |
| EP-B | By | By |
| EP-A | By staphylococcus aureus 1.3log reduction/6 hours bacillus pyocyaneus 0.7log reduction/6 hours | By |
This embodiment shows, comprises in the preparation of chlorine oxygen component and boric acid existing glycerol further to improve the inhibitor effectiveness of compositions.The preparation 11 that comprises whole chlorine oxygen components, glycerol and boric acid is by whole USP, EP-A and EP-B testing standard.Preparation 10 does not all pass through.
Embodiment 6
Preparation is also tested a kind of preparation.Measurement result is summarized as follows:
| Component | Preparation 12 |
| Brimonidine tartrate (3) % (w/v) | 0.15 |
| Chlorine oxygen component (2) (ppm) | 150 |
| Pemulen TR-2(1) ％(w/v) | 0.1 |
| Polyoxyethylene sorbitan monoleate % (w/v) | 1 |
| Oleum Ricini % (w/v) | 1.25 |
| Glycerol % (w/v) | 1 |
| PH | 7.3 |
| Purify waste water | QS 100％ |
| Boric acid % (w/v) | 0.6 |
| Mannitol % (w/v) | - |
(3) 5-bromo-6-(2-imidazoline-2-base is amino) quinoxaline tartrate
Said preparation is by whole USP, EP-A and EP-B testing standard.In addition, the compositions of the described preparation of O/w emulsion form for effectively sending brimonidine to the eye of the mankind or animal.
Although the present invention describes with regard to a plurality of certain embodiments and embodiment, be understood that the present invention is not limited to this, and can in the scope of following claim, implement the present invention in a different manner.
Claims (44)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/400,893 | 2003-03-27 | ||
| US10/400,893 US20040191332A1 (en) | 2003-03-27 | 2003-03-27 | Preserved ophthalmic compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1794973A true CN1794973A (en) | 2006-06-28 |
| CN100528139C CN100528139C (en) | 2009-08-19 |
Family
ID=32989309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004800139343A Expired - Fee Related CN100528139C (en) | 2003-03-27 | 2004-03-23 | Preserved ophthalmic compositions |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20040191332A1 (en) |
| EP (1) | EP1605912A2 (en) |
| JP (1) | JP2006521362A (en) |
| CN (1) | CN100528139C (en) |
| AU (1) | AU2004226466B2 (en) |
| BR (1) | BRPI0408827A (en) |
| CA (1) | CA2520521C (en) |
| NZ (1) | NZ542727A (en) |
| WO (1) | WO2004087098A2 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI673071B (en) * | 2017-01-13 | 2019-10-01 | National Taipei University Of Technology | Ophthalmic composition |
| CN111565761A (en) * | 2017-11-15 | 2020-08-21 | 派瑞根佰欧泰克公司 | Fluorescein and procaine butoxide composition |
| TWI798498B (en) * | 2019-10-23 | 2023-04-11 | 永勝光學股份有限公司 | Solution with high antimicrobial ability and lubricating effect |
| CN115996742A (en) * | 2020-03-25 | 2023-04-21 | 奥夫博医疗创新有限公司 | Methods and agents for glaucoma |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050026924A1 (en) * | 2000-07-14 | 2005-02-03 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
| US8858961B2 (en) | 2000-07-14 | 2014-10-14 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
| US8529927B2 (en) * | 2004-04-30 | 2013-09-10 | Allergan, Inc. | Alpha-2 agonist polymeric drug delivery systems |
| US7465412B2 (en) * | 2004-10-28 | 2008-12-16 | Ppg Industries Ohio, Inc. | Calcium hypochlorite composition |
| US9452133B2 (en) | 2005-04-25 | 2016-09-27 | KEM Patent Holdings, LLC | Method for preventing nasolacrimal duct obstruction |
| IL168603A (en) * | 2005-05-16 | 2011-05-31 | Resdevco Res And Dev Co | Pharmaceutical or cosmetic composition for the prevention and treatment of irritation of mucous cells or skin cells |
| CN101778621B (en) | 2007-07-26 | 2015-09-09 | Azad药物股份公司 | Pharmaceutical preparations containing electrochemically activated hypochlorite solutions |
| US20090220618A1 (en) * | 2008-02-29 | 2009-09-03 | Erning Xia | Pharmaceutical formulations comprising polyanionic materials and source of hydrogen peroxide |
| KR20130092957A (en) | 2010-04-07 | 2013-08-21 | 알러간, 인코포레이티드 | Combinations of preservative compositions for ophthalmic formulations |
| EP2555748A2 (en) | 2010-04-07 | 2013-02-13 | Allergan, Inc. | Combinations of preservatives for ophthalmic compositions |
| US20140163080A1 (en) * | 2011-02-03 | 2014-06-12 | Gnt, Llc | Compositions and Methods for Treatment of Glaucoma |
| EP2630952A1 (en) * | 2012-02-23 | 2013-08-28 | Novagali Pharma S.A. | Self-preserved oil dispersions comprising boric acid |
| WO2014074605A1 (en) * | 2012-11-08 | 2014-05-15 | Allergan, Inc. | Preserved topical formulations with improved antimicrobial activity |
| US20140378401A1 (en) * | 2013-06-21 | 2014-12-25 | Gnt, Llc | Ophthalmic Lipophilic and Hydrophilic Drug Delivery Vehicle Formulations |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US71874A (en) * | 1867-12-10 | haskell | ||
| US32201A (en) * | 1861-04-30 | John Neumann | Faucet | |
| US23098A (en) * | 1859-03-01 | Improvement in horse-rakes | ||
| US198209A (en) * | 1877-12-18 | Improvement in the manufacture of metallic leaf | ||
| US27811A (en) * | 1860-04-10 | Joseph kbech | ||
| US3278447A (en) * | 1963-12-02 | 1966-10-11 | Cloro Bac Products Inc | Process for stabilizing chlorine dioxide solution |
| BE795970A (en) * | 1972-02-29 | 1973-08-27 | Pfizer | NEW DERIVATIVES OF QUINOLEINE, QUINOXALINE AND QUINAZOLINE ER PHARMACEUTICAL COMPOSITION CONTAINING THEM |
| US3910296A (en) * | 1973-04-20 | 1975-10-07 | Allergan Pharma | Method of removing proteinaceous deposits from contact lenses |
| US4089969A (en) * | 1976-07-14 | 1978-05-16 | Syntex (U.S.A.) Inc. | 5-Aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof |
| US4136173A (en) * | 1977-01-31 | 1979-01-23 | American Home Products Corp. | Mixed xanthan gum and locust beam gum therapeutic compositions |
| US4136178A (en) * | 1977-01-31 | 1979-01-23 | American Home Products Corp. | Locust bean gum therapeutic compositions |
| US4136177A (en) * | 1977-01-31 | 1979-01-23 | American Home Products Corp. | Xanthan gum therapeutic compositions |
| US4474787A (en) * | 1977-05-04 | 1984-10-02 | Fisons Limited | 7,6 Dioxo-4H,6H-pyrano[3,2-g]quinoline dicarboxylic acids and anti-allergic use thereof |
| ATE6466T1 (en) * | 1979-10-26 | 1984-03-15 | Smith And Nephew Associated Companies P.L.C. | AUTOCLAVABLE EMULSIONS. |
| JPS5746986A (en) * | 1980-09-02 | 1982-03-17 | Dai Ichi Seiyaku Co Ltd | Pyrido(1,2,3-de)(1,4)benzoxazine derivative |
| US4411801A (en) * | 1981-09-17 | 1983-10-25 | Nl Industries, Inc. | Low solids well servicing fluids |
| US4525346A (en) * | 1981-09-28 | 1985-06-25 | Alcon Laboratories, Inc. | Aqueous antimicrobial ophthalmic solutions |
| US4758595A (en) * | 1984-12-11 | 1988-07-19 | Bausch & Lomb Incorporated | Disinfecting and preserving systems and methods of use |
| USRE32672E (en) * | 1985-09-09 | 1988-05-24 | Allergan, Inc. | Method for simultaneously cleaning and disinfecting contact lenses using a mixture of peroxide and proteolytic enzyme |
| FR2588189B1 (en) * | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | LIQUID-GEL PHASE TRANSITION PHARMACEUTICAL COMPOSITION |
| US5089509A (en) * | 1988-09-15 | 1992-02-18 | Allergan, Inc. | Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity |
| US4861514A (en) * | 1988-06-08 | 1989-08-29 | The Drackett Company | Compositions containing chlorine dioxide and their preparation |
| CA2003198C (en) * | 1988-11-29 | 1995-03-21 | Anthony J. Dziabo, Jr. | Aqueous ophthalmic solutions and method for preserving same |
| US5021416A (en) * | 1989-10-31 | 1991-06-04 | Allergan, Inc. | Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure |
| US5089053A (en) * | 1989-11-09 | 1992-02-18 | Polymer Technology Corporation | Contact lens cleaning material and method |
| US5145643A (en) * | 1990-01-05 | 1992-09-08 | Allergan, Inc. | Nonoxidative ophthalmic compositions and methods for preserving and using same |
| US5212162A (en) * | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| IL101007A (en) * | 1992-02-18 | 1997-08-14 | Pharmos Ltd | Dry stable compositions prepared by lyophilization |
| US5366739A (en) * | 1992-08-06 | 1994-11-22 | Deo Corporation | Method of ophthalmic drug delivery |
| WO1994005298A1 (en) * | 1992-08-28 | 1994-03-17 | Pharmos Corporation | Submicron emulsions as ocular drug delivery vehicles |
| US5688819A (en) * | 1992-09-21 | 1997-11-18 | Allergan | Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
| US5922773A (en) * | 1992-12-04 | 1999-07-13 | The Children's Medical Center Corp. | Glaucoma treatment |
| ES2199956T3 (en) * | 1992-12-17 | 2004-03-01 | Advanced Medical Optics, Inc. | DISINFECTING SOLUTION OF CONTACT LENSES CONTAINING AN OXIDIZING AGENT AND POLIVINYLPIRROLIDONE. |
| US5648074A (en) * | 1993-05-25 | 1997-07-15 | Allergan | Compositions and methods for disinfecting contact lenses and reducing proteinaceous deposit formation |
| JP3683908B2 (en) * | 1993-10-13 | 2005-08-17 | アラーガン、インコーポレイテッド | Method of using (2-imidazolin-2-ylamino) quinoxaline derivative |
| JPH07316038A (en) * | 1994-05-23 | 1995-12-05 | Ikeda Mohandou:Kk | Pharmaceutical composition for mucosal administration |
| WO1996033697A1 (en) * | 1995-04-24 | 1996-10-31 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Self-emulsifiable formulation producing an oil-in-water emulsion |
| US5858401A (en) * | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
| US6000534A (en) * | 1996-08-16 | 1999-12-14 | Allergan Sales, Inc. | Contact lens disinfecting device and disinfection system |
| WO1998013040A1 (en) * | 1996-09-26 | 1998-04-02 | Rohto Pharmaceutical Co., Ltd. | Eyedrops |
| US5858346A (en) * | 1997-05-09 | 1999-01-12 | Allergan | Compositions and methods for enhancing contact lens wearability |
| US5993864A (en) * | 1997-07-11 | 1999-11-30 | Kross; Robert D. | Chlorine dioxide chelate compositions and method of use |
| CA2294033C (en) * | 1997-07-29 | 2007-01-09 | Pharmacia & Upjohn Company | Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation |
| DE69804624T2 (en) * | 1997-07-29 | 2002-09-19 | PHARMACIA & UPJOHN CO., KALAMAZOO | SELF-TEMPERATURE FORMULATION CONTAINING LIPOPHILE COMPOUNDS |
| US6841684B2 (en) * | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
| US5981607A (en) * | 1998-01-20 | 1999-11-09 | Allergan | Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers |
| JP2002523475A (en) * | 1998-09-02 | 2002-07-30 | アラーガン・セイルズ・インコーポレイテッド | Preserved cyclodextrin-containing composition |
| MXPA01003507A (en) * | 1998-10-08 | 2002-06-26 | Hampar L Karagoezian | Synergistic antimicrobial, dermatological and ophthalmic preparations containing chlorite and hydrogen peroxide. |
| WO2000019981A1 (en) * | 1998-10-08 | 2000-04-13 | Karagoezian Hampar L | Synergistic antimicrobial, dermatological and ophthalmic preparations containing chlorite and hydrogen peroxide |
| US6057289A (en) * | 1999-04-30 | 2000-05-02 | Pharmasolutions, Inc. | Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system |
| US20040214829A1 (en) * | 2000-07-14 | 2004-10-28 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
| CA2416169C (en) * | 2000-07-14 | 2008-09-23 | Allergan, Inc. | Compositions containing therapeutically active components having enhanced solubility |
| RU2311928C2 (en) * | 2000-07-14 | 2007-12-10 | Аллерган Инк. | Composition containing alpha-2-adrenergic agonists |
| US20040219219A1 (en) * | 2000-07-14 | 2004-11-04 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
| CA2428985C (en) * | 2000-11-08 | 2011-05-24 | Bio-Concept Laboratories | Improved ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers |
| US20020198209A1 (en) * | 2001-05-03 | 2002-12-26 | Allergan Sales Inc. | Compositions having enhanced pharmacokinetic characteristics |
| US7045121B2 (en) * | 2001-12-14 | 2006-05-16 | Allergan, Inc. | Ophthalmic compositions for lubricating eyes and methods for making and using same |
| US6982079B2 (en) * | 2002-04-26 | 2006-01-03 | Allergan, Inc. | Compositions for treating hyperemia |
| US20040137079A1 (en) * | 2003-01-08 | 2004-07-15 | Cook James N. | Contact lens and eye drop rewetter compositions and methods |
| US6635654B1 (en) * | 2003-01-09 | 2003-10-21 | Allergan, Inc. | Ophthalmic compositions containing loratadine |
| US7087190B2 (en) * | 2003-03-20 | 2006-08-08 | Ecolab Inc. | Composition for the production of chlorine dioxide using non-iodo interhalides or polyhalides and methods of making and using the same |
| US20050250737A1 (en) * | 2003-11-12 | 2005-11-10 | Allergan, Inc. | Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods |
-
2003
- 2003-03-27 US US10/400,893 patent/US20040191332A1/en not_active Abandoned
-
2004
- 2004-03-23 CA CA2520521A patent/CA2520521C/en not_active Expired - Fee Related
- 2004-03-23 EP EP04758235A patent/EP1605912A2/en not_active Withdrawn
- 2004-03-23 AU AU2004226466A patent/AU2004226466B2/en not_active Ceased
- 2004-03-23 WO PCT/US2004/008913 patent/WO2004087098A2/en not_active Ceased
- 2004-03-23 JP JP2006507503A patent/JP2006521362A/en active Pending
- 2004-03-23 BR BRPI0408827-1A patent/BRPI0408827A/en not_active Application Discontinuation
- 2004-03-23 CN CNB2004800139343A patent/CN100528139C/en not_active Expired - Fee Related
- 2004-03-23 NZ NZ542727A patent/NZ542727A/en not_active IP Right Cessation
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI673071B (en) * | 2017-01-13 | 2019-10-01 | National Taipei University Of Technology | Ophthalmic composition |
| CN111565761A (en) * | 2017-11-15 | 2020-08-21 | 派瑞根佰欧泰克公司 | Fluorescein and procaine butoxide composition |
| US11452779B2 (en) | 2017-11-15 | 2022-09-27 | Paragon BioTeck, Inc. | Fluorescein and benoxinate compositions |
| TWI798498B (en) * | 2019-10-23 | 2023-04-11 | 永勝光學股份有限公司 | Solution with high antimicrobial ability and lubricating effect |
| CN115996742A (en) * | 2020-03-25 | 2023-04-21 | 奥夫博医疗创新有限公司 | Methods and agents for glaucoma |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006521362A (en) | 2006-09-21 |
| CA2520521C (en) | 2013-05-14 |
| CA2520521A1 (en) | 2004-10-14 |
| BRPI0408827A (en) | 2006-04-04 |
| US20040191332A1 (en) | 2004-09-30 |
| CN100528139C (en) | 2009-08-19 |
| AU2004226466B2 (en) | 2009-01-22 |
| EP1605912A2 (en) | 2005-12-21 |
| AU2004226466A1 (en) | 2004-10-14 |
| WO2004087098A2 (en) | 2004-10-14 |
| WO2004087098A3 (en) | 2005-06-02 |
| NZ542727A (en) | 2008-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1794973A (en) | Preserved ophthalmic compositions | |
| CN1441679A (en) | Compositions containing therapentically active components having enhanced solubility | |
| US20110251285A1 (en) | Combinations of preservatives for ophthalmic compositions | |
| JP2010132681A (en) | Composition having enhanced pharmacokinetic characteristics | |
| CN109789125B (en) | Pharmaceutical composition containing a therapeutic agent based on polymyxin B/trimethoprim | |
| JP6800939B2 (en) | Methods and Compositions for Daily Ophthalmic Administration of Phentolamine to Improve Visual Function | |
| CN1791383A (en) | Self-emulsifying compositions, methods of use and preparation | |
| AU2001273268A1 (en) | Compositions containing therapeutically active components having enhanced solubility | |
| CN1116407A (en) | Preservative system for contact lens solutions | |
| CN1130204C (en) | Pharmaceutical compsns. with antimicrobial activity | |
| JP6466504B2 (en) | Alpha-2 adrenergic agonist with long-term intraocular pressure reduction effect | |
| CN1140988A (en) | Liquid ophthalmic sustained release delivery system | |
| CN1137679C (en) | Water-soluble eye drops | |
| CN100341412C (en) | Methods for preserving ophthalmic solutions and preserved ophtalmic solutions | |
| CN1374874A (en) | Use of fatty acid/amino acid soaps to enhance antimicrobial effectiveness of topical pharmaceutical compositions | |
| HK1058764A (en) | Compositions containing therapeutically active components having enhanced solubility | |
| JP2004528369A (en) | Compositions with improved pharmacokinetic properties | |
| CN1148810A (en) | Medicinal composition for treating glaucoma | |
| CN1814299A (en) | Macrolide antibiotics sodium hyaluronate eye transfer system | |
| CN1704067A (en) | Medicine composition for ophthalmology department | |
| CN1899286A (en) | Racanisodamine eye drops | |
| CN1163266C (en) | Eye drops for treating conjunctivitis and keratitis | |
| KR20250141793A (en) | Alpha-2-adrenergic agonists to improve vision | |
| AU2005234735A1 (en) | Compositions containing therapeutically active components having enhanced solubility | |
| CN1909898A (en) | Eye drop composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090819 Termination date: 20150323 |
|
| EXPY | Termination of patent right or utility model |